Home » Drug Information » FDA Approved Drugs » 1996
Medical Areas: Gastroenterology | Neurology | Pediatrics/Neonatology | Infections and Infectious Diseases | Vaccines
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Merrem I.V. (meropenem)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Approval Status: Approved June 1996
Treatment Area: intra-abdominal infections and bacterial meningitis
Merrem I.V. has been recommended for use in treating adults and
children with certain serious bacterial infections. Merrem is
indicated for the treatment of complicated intra-abdominal
infections in adults and pediatric subjects and for the treatment
of bacterial meningitis in pediatric subjects.
Merrem is the first carbapenem antibiotic available in the
United States that can be used in children and does not need to be
administered in combination with an enzyme inhibitor to prevent its
renal breakdown. Merrem is a potent antibiotic with activity
against many different bacteria, including some that are resistant
to other antibiotics.
Merrem can be administered by intravenous infusion or
intravenous bolus injection.
Merrem is well tolerated at high doses and has been shown to
have a low incidence of adverse events. Systemic adverse events
reported in studies with Merrem were typical of those seen with
other intravenous antibiotics and included diarrhea, nausea,
vomiting, and headache.